Whitepapers

With the ever-growing demand for vaccines and advanced therapy products, cell culture platforms are challenged to provide cost-effective, high-yield production that can easily transition from process development through large-scale manufacturing. Ann Rossi Bilodeau, Ph.D. from Corning Life Sciences discusses what the Corning® CellCube® has to offer for the end user.

Wyatt's instruments and techniques constitute platform methods for effective product and process development, as well as quality control, of AAVs for gene therapy.

Multi-angle light scattering is a powerful technology for the biophysical characterization of biologics and LNPs. It can also serve as an effective PAT tool to monitor product attributes during DSP.

Light scattering facilitates vaccine development by enabling the analysis of size, shape, molar mass, and other parameters derived from these properties.

Many biologics must undergo freeze-thaw stability testing during product development. We describe a method for performing this test using a DLS plate reader.

SEC-MALS quantifies biophysical attributes of mRNA, including molar mass, percent aggregates, Rg and Rh, and how they are affected by formulation and storage conditions.

Join Eurofins BioPharma Product Testing and Vanrx (now part of Cytiva), for an in-depth discussion covering ways to eliminate human error and other associated risks when producing small batches of sterile GMP product for Phase 1 and 2 clinical trials. Learn how we can help increase speed and flexibility to drive your drug product into the clinic, and ultimately to patients faster.

Eurofins BioPharma Product Testing can help eliminate human error and other associated risks when producing small batches of sterile GMP product for Phase I-II trials using our state-of-the-art Vanrx Microcell Vial Filler.

Innovations in the use of viral vectors as a gene delivery vehicle are a key factor in the growth of the gene and cell therapy field. However, the long-term impact of viral vectors requires continued research in their design to address both efficacy and the problems with immunogenicity and toxicity.

There’s no doubt clinical research has changed. With 77% of surveyed pharma executives planning to run a hybrid or decentralized trial this year, it’s important to understand the benefits of web-enabled research tools and how they work. Learn the benefits of DCTs with this eBook.